Kelun-Biotech's SKB535 Receives Approval for Clinical Trials in Advanced Solid Tumors
Key Insights
Kelun-Biotech (search)'s SKB535, an innovative antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials targeting advanced solid tumors (search).
The drug was developed using Kelun-Biotech (search)’s OptiDC platform and has demonstrated promising preclinical results, warranting further clinical investigation.
Kelun-Biotech (search) has partnered with Merck & Co. (search), Inc. for the development of SKB535, potentially receiving milestone payments and royalties upon successful commercialization.
Kelun-Biotech (search) Biopharmaceutical Co., Ltd. has announced that its investigational new drug, SKB535, has received approval from the National Medical Products Administration (NMPA) in China to proceed with clinical trials. This antibody-drug conjugate (ADC) is designed for the treatment of advanced solid tumors (search).
SKB535: A Novel ADC for Solid Tumors
SKB535 was developed using Kelun-Biotech (search)’s proprietary OptiDC platform. Preclinical studies have indicated promising efficacy and safety profiles, leading to the NMPA's decision to allow clinical trials. The drug aims to address the unmet medical need in patients with advanced solid tumors (search), offering a potential new treatment option.
Partnership with Merck
Kelun-Biotech (search) has entered into a collaboration with Merck & Co. (search), Inc. to further the development and commercialization of SKB535. The agreement includes potential milestone payments and royalties to Kelun-Biotech upon successful commercialization, highlighting the industry's interest in this novel ADC.
Clinical Trial Focus
The clinical trials will evaluate the safety, tolerability, and preliminary efficacy of SKB535 in patients with advanced solid tumors (search). Specific details regarding trial design, patient population, and endpoints will be disclosed as the trials progress. The focus will be on assessing the drug's potential to improve outcomes for patients who have limited treatment options.